Media coverage about Supernus Pharmaceuticals (NASDAQ:SUPN) has trended somewhat positive recently, Accern reports. Accern identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Supernus Pharmaceuticals earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave news articles about the specialty pharmaceutical company an impact score of 46.0234077297687 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

These are some of the media stories that may have effected Accern’s rankings:

Shares of Supernus Pharmaceuticals (SUPN) opened at $46.90 on Monday. Supernus Pharmaceuticals has a twelve month low of $23.10 and a twelve month high of $50.04. The firm has a market cap of $2,400.00, a P/E ratio of 42.64 and a beta of 1.17.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.27 by $0.02. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. The company had revenue of $80.40 million during the quarter, compared to the consensus estimate of $78.74 million. The business’s revenue for the quarter was up 41.5% on a year-over-year basis. equities analysts predict that Supernus Pharmaceuticals will post 1.07 earnings per share for the current year.

A number of brokerages have issued reports on SUPN. Zacks Investment Research upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a research report on Wednesday, January 10th. BidaskClub raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 11th. Cowen set a $50.00 price target on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, October 23rd. B. Riley reaffirmed a “buy” rating and set a $50.00 price target on shares of Supernus Pharmaceuticals in a report on Monday, November 20th. Finally, Stifel Nicolaus raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $47.00 price target for the company in a report on Tuesday, November 7th. Three equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $49.90.

In related news, CFO Gregory S. Patrick sold 50,000 shares of the stock in a transaction that occurred on Thursday, January 11th. The shares were sold at an average price of $43.56, for a total value of $2,178,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Victor Vaughn sold 55,000 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $40.11, for a total transaction of $2,206,050.00. The disclosure for this sale can be found here. In the last three months, insiders sold 145,750 shares of company stock valued at $6,173,173. 6.70% of the stock is owned by insiders.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Supernus Pharmaceuticals (SUPN) Share Price” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2018/01/22/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-supernus-pharmaceuticals-supn-share-price.html.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Insider Buying and Selling by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.